NeuroMetrix
An innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. It introduced the first wearable nerve stimulator for managing chronic pain and invented the concept of automated nerve testing. The company is a wholly-owned subsidiary of electroCore, Inc. and continues to provide its Quell products and services under its established brand.
History
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The company introduced the first wearable nerve stimulator for managing chronic pain and invented the concept of automated nerve testing. NeuroMetrix, Inc. is a wholly-owned subsidiary of electroCore, Inc. and continues to provide its Quell products and services under its established brand.
Products and positioning
Quell Fibromyalgia
An advanced wearable neuromodulator that is the first and only FDA authorized medical device that helps reduce the symptoms of fibromyalgia.
Recent events
Reported
NeuroMetrix launches Quell Watch App[5]
NeuroMetrix announced the launch of the Quell Watch App, which was available for download from the Apple App Store.
Reported
NeuroMetrix announces Quell knee-pain marketing initiative[6]
NeuroMetrix announced a Quell marketing initiative focused on chronic knee pain, including direct-to-consumer digital marketing and information for physicians and other health care providers.
Reported
NeuroMetrix reports Q2 2020 financial results[6]
NeuroMetrix reported financial and business highlights for the quarter ended June 30, 2020, including revenue of $1.4 million and a net loss of $0.9 million.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/neurometrix · Editorial policy · How profiles are compiled